IDEAS home Printed from https://ideas.repec.org/a/eee/hepoli/v115y2014i1p82-91.html
   My bibliography  Save this article

Effectiveness and cost-effectiveness of different immunization strategies against whooping cough to reduce child morbidity and mortality

Author

Listed:
  • Rivero-Santana, Amado
  • Cuéllar-Pompa, Leticia
  • Sánchez-Gómez, Luis M.
  • Perestelo-Pérez, Lilisbeth
  • Serrano-Aguilar, Pedro

Abstract

In the last years there has been a significant increase in reported cases of pertussis in developed countries, in spite of high rates of childhood immunization. Health institutions have recommended different vaccination strategies to reduce child morbidity and mortality: vaccination of adolescents and adults, pregnant women, people in contact with the newborn (cocoon strategy) and health care workers. The aim of this paper is to review the scientific evidence supporting these recommendations.

Suggested Citation

  • Rivero-Santana, Amado & Cuéllar-Pompa, Leticia & Sánchez-Gómez, Luis M. & Perestelo-Pérez, Lilisbeth & Serrano-Aguilar, Pedro, 2014. "Effectiveness and cost-effectiveness of different immunization strategies against whooping cough to reduce child morbidity and mortality," Health Policy, Elsevier, vol. 115(1), pages 82-91.
    • Handle: RePEc:eee:hepoli:v:115:y:2014:i:1:p:82-91
    DOI: 10.1016/j.healthpol.2013.12.007
    as

    Download full text from publisher

    File URL: http://www.sciencedirect.com/science/article/pii/S016885101300328X
    Download Restriction: Full text for ScienceDirect subscribers only
    File URL: https://libkey.io/10.1016/j.healthpol.2013.12.007?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Laurent Coudeville & Annelies Van Rie & Denis Getsios & J Jaime Caro & Pascal Crépey & Van Hung Nguyen, 2009. "Adult Vaccination Strategies for the Control of Pertussis in the United States: An Economic Evaluation Including the Dynamic Population Effects," PLOS ONE, Public Library of Science, vol. 4(7), pages 1-9, July.
    2. Robin de Vries & Mirjam Kretzschmar & Joop F P Schellekens & Florens G A Versteegh & Tjalke A Westra & John J Roord & Maarten J Postma, 2010. "Cost-Effectiveness of Adolescent Pertussis Vaccination for The Netherlands: Using an Individual-Based Dynamic Model," PLOS ONE, Public Library of Science, vol. 5(10), pages 1-11, October.
    3. Dorota Girard, 2010. "The distribution over time of costs and social net benefits for pertussis immunization programs," International Journal of Health Economics and Management, Springer, vol. 10(1), pages 1-27, March.
    4. Julio López-Bastida & Juan Oliva & Fernando Antoñanzas & Anna García-Altés & Ramón Gisbert & Javier Mar & Jaume Puig-Junoy, 2010. "Spanish recommendations on economic evaluation of health technologies," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 11(5), pages 513-520, October.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Feng Jiang & Ning Tang & Yuanxue Gao & Jun Feng & Ying Wang & Bin Qu, 2022. "Knowledge and Willingness toward Vaccination among Pregnant Women: Comparison between Pertussis and Influenza," IJERPH, MDPI, vol. 19(21), pages 1-15, October.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. SeungJin Bae & SooOk Lee & Eun Bae & Sunmee Jang, 2013. "Korean Guidelines for Pharmacoeconomic Evaluation (Second and Updated Version)," PharmacoEconomics, Springer, vol. 31(4), pages 257-267, April.
    2. Elisabetta De Cao & Alessia Melegaro & Rogier Klok & Maarten Postma, 2014. "Optimising Assessments of the Epidemiological Impact in the Netherlands of Paediatric Immunisation with 13-Valent Pneumococcal Conjugate Vaccine Using Dynamic Transmission Modelling," PLOS ONE, Public Library of Science, vol. 9(4), pages 1-9, April.
    3. Antonio García-Ruiz & Lucía Pérez-Costillas & Ana Montesinos & Javier Alcalde & Itziar Oyagüez & Miguel Casado, 2012. "Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses," Health Economics Review, Springer, vol. 2(1), pages 1-12, December.
    4. M. Barbieri & H. Weatherly & R. Ara & H. Basarir & M. Sculpher & R. Adams & H. Ahmed & C. Coles & T. Guerrero-Urbano & C. Nutting & M. Powell, 2014. "What is the Quality of Economic Evaluations of Non-Drug Therapies? A Systematic Review and Critical Appraisal of Economic Evaluations of Radiotherapy for Cancer," Applied Health Economics and Health Policy, Springer, vol. 12(5), pages 497-510, October.
    5. Giovanni Gabutti & Maria Cristina Rota, 2012. "Pertussis: A Review of Disease Epidemiology Worldwide and in Italy," IJERPH, MDPI, vol. 9(12), pages 1-13, December.
    6. Laura Amanda Vallejo-Aparicio & Jesús Molina & Iñigo Ojanguren & Ana Viejo Casas & Alicia Huerta & Henrik Svedsater, 2020. "Cost–consequence analysis of fluticasone furoate/vilanterol for asthma management in Spain: an analysis based on the Salford Lung Study in asthma," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(1), pages 7-17, February.
    7. Sun, Ruoyan, 2013. "Kinetics of jobs in multi-link cities with migration-driven aggregation process," Economic Modelling, Elsevier, vol. 30(C), pages 36-41.
    8. Santiago Grau & Rafael Cámara & Manuel Jurado & Jaime Sanz & Belén Aragón & Irmina Gozalbo, 2018. "Cost-effectiveness of posaconazole tablets versus fluconazole as prophylaxis for invasive fungal diseases in patients with graft-versus-host disease after allogeneic hematopoietic stem cell transplant," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(4), pages 627-636, May.
    9. B. Rodríguez-Sánchez & S. Daugbjerg & L. M. Peña-Longobardo & J. Oliva-Moreno & I. Aranda-Reneo & A. Cicchetti & J. López-Bastida, 2023. "Does the inclusion of societal costs change the economic evaluations recommendations? A systematic review for multiple sclerosis disease," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(2), pages 247-277, March.
    10. Juliano Marçal Lopes & Coralys Colon Morales & Michelle Alvarado & Vidal Augusto Z. C. Melo & Leonardo Batista Paiva & Eduardo Mario Dias & Panos M. Pardalos, 2022. "Optimization methods for large-scale vaccine supply chains: a rapid review," Annals of Operations Research, Springer, vol. 316(1), pages 699-721, September.
    11. Erik Nord, 2011. "Discounting future health benefits: the poverty of consistency arguments," Health Economics, John Wiley & Sons, Ltd., vol. 20(1), pages 16-26, January.
    12. Lisanne I. Lier & Judith E. Bosmans & Hein P. J. Hout & Lidwine B. Mokkink & Wilbert B. Hout & G. Ardine Wit & Carmen D. Dirksen & Henk L. G. R. Nies & Cees M. P. M. Hertogh & Henriëtte G. Roest, 2018. "Consensus-based cross-European recommendations for the identification, measurement and valuation of costs in health economic evaluations: a European Delphi study," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(7), pages 993-1008, September.
    13. Ralph Schmidt & Istvan Majer & Natalia García Román & Alejandra Rivas Basterra & ElizaBeth Grubb & Constancio Medrano López, 2017. "Palivizumab in the prevention of severe respiratory syncytial virus infection in children with congenital heart disease; a novel cost-utility modeling study reflecting evidence-based clinical pathways," Health Economics Review, Springer, vol. 7(1), pages 1-14, December.
    14. José Rodríguez Barrios & Ferran Pérez Alcántara & Carlos Crespo Palomo & Paloma González García & Enrique Antón De Las Heras & Max Brosa Riestra, 2012. "The use of cost per life year gained as a measurement of cost-effectiveness in Spain: a systematic review of recent publications," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(6), pages 723-740, December.
    15. Dambar Uprety, 2019. "Skilled migration and health outcomes in developing countries," International Journal of Health Economics and Management, Springer, vol. 19(1), pages 1-14, March.
    16. Caroline Orset, 2018. "People’s perception and cost-effectiveness of home confinement during an influenza pandemic: evidence from the French case," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(9), pages 1335-1350, December.
    17. Ali Tafazzoli & Odette S. Reifsnider & Leana Bellanca & Jack Ishak & Marc Carrasco & Pal Rakonczai & Matthew Stargardter & Stephan Linden, 2023. "A European multinational cost-effectiveness analysis of empagliflozin in heart failure with reduced ejection fraction," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(9), pages 1441-1454, December.
    18. Blanca Gros & Antonio Galán & Emilio González-Parra & Jose Herrero & Maria Echave & Stefan Vegter & Keith Tolley & Itziar Oyagüez, 2015. "Cost effectiveness of lanthanum carbonate in chronic kidney disease patients in Spain before and during dialysis," Health Economics Review, Springer, vol. 5(1), pages 1-9, December.
    19. Pascal Crépey & Esther Redondo & Javier Díez-Domingo & Raúl Ortiz de Lejarazu & Federico Martinón-Torres & Ángel Gil de Miguel & Juan Luis López-Belmonte & Fabián P Alvarez & Hélène Bricout & Míriam S, 2020. "From trivalent to quadrivalent influenza vaccines: Public health and economic burden for different immunization strategies in Spain," PLOS ONE, Public Library of Science, vol. 15(5), pages 1-19, May.
    20. Kobelt, G., 2013. "Health Economics: An Introduction to Economic Evaluation," Monographs, Office of Health Economics, number 000004.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:hepoli:v:115:y:2014:i:1:p:82-91. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu or the person in charge (email available below). General contact details of provider: http://www.elsevier.com/locate/healthpol .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.